Morgan Stanley Maintains Overweight on Akero Therapeutics, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Akero Therapeutics (NASDAQ:AKRO) but lowered the price target from $70 to $33.
October 11, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Akero Therapeutics but lowered the price target from $70 to $33.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of Akero Therapeutics in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100